Finnzymes Oy – Trademark Portfolio
Entity Type: 09
Finnzymes Oy holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 4 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 5 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include PHIRE and PHUSION. The owner is based in Vantaa.
Ratastie 2
Vantaa 01620 , FI
Showing of trademarks Trademarks
Trademark Classifications
Finnzymes Oy's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Finnzymes Oy have?
Finnzymes Oy has 7 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 cancelled.
What trademark classes does Finnzymes Oy file in?
Finnzymes Oy files trademarks across 5 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 1 (Chemicals), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Finnzymes Oy's most well-known trademarks?
Finnzymes Oy's registered trademark portfolio includes well-known marks such as PHIRE and PHUSION. These are among 2 currently registered trademarks in the portfolio.
What is Finnzymes Oy's trademark registration success rate?
Finnzymes Oy has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.